VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that following an audit of its Multikine® manufacturing plant and laboratories by a European Union Qualified Person (QP), the CEL-SCI facilities were found to be in a high level of compliance with the Good Manufacturing Practices (GMP) Directives of the International Conference on Harmonization (ICH). The QP’s finding clears the way for CEL-SCI to export Multikine to the European Union (EU) for use in its Phase III clinical trial in head and neck cancer patients.
